Efficacy, safety and tolerability of CK-2127107 in ALS

Diagnosis ALS
Study phase Completed
Participating centres UMC Utrecht

A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS).

This study is to assess the effect of CK-2127107 versus placebo on respiratory function and hand grip strength in patients with ALS.

Overall enrolment: 445 patients

Centres: 47 sites in the US, 5 sites in Australia, 9 sites in Canada, 1 site in Spain and 1 site in The Netherlands (UMCU)

Read more on clinicaltrialsregister.eu Read more on clinicaltrials.gov